Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform

Bruce Meiklejohn

Bruce Meiklejohn is a principal fellow, regulatory COE-biotech at Eli Lilly and Company

Articles by Bruce Meiklejohn